Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

An uro-genital condition treatment system

A reproductive system, disease technology, applied in the field of treatment of urogenital system diseases

Inactive Publication Date: 2008-08-27
ZENGEN
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although effective, some strains of S. aureus have become resistant and only a few antibiotics are effective against methicillin-resistant S. aureus (MRSA)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • An uro-genital condition treatment system
  • An uro-genital condition treatment system
  • An uro-genital condition treatment system

Examples

Experimental program
Comparison scheme
Effect test

Embodiment I

[0042] The purpose of this example is to clarify the antimicrobial properties of α-MSH and / or its derivatives. Here, Staphylococcus aureus is taken as an example. The Staphylococcus aureus culture (ATCC 29213) was provided by the Department of Microbiology of Ospedale Maggiore di Milano. Staphylococcus aureus (in Hank's balanced salt solution 1×10 6 / Ml) In the presence or absence of α-MSH (1-13) (serial number 4), α-MSH (11-13) (serial number 1) or KPV dimer, culture at 37°C 2 Hour, the peptide concentration is 10 -15 -10 -4 M. The cells were then rinsed in cold distilled water and diluted with HBSS to 100 organisms / ml. Spread a microliter aliquot on a plasma agar plate and incubate at 37°C for 24 hours. Then the viability of the microorganisms was evaluated based on the colonies formed. In another experiment, the bacteria concentration was 10 5 Add different peptides and 500 units of urokinase (growth promoter of Staphylococcus aureus) to 100 ml of culture solution, and shake cu...

Embodiment II

[0045] The purpose of this example is to clarify the antifungal properties of α-MSH and / or its derivatives. The experimental strain selected here is Candida albicans.

[0046] The clinical isolate of Candida albicans was provided by the Department of Microbiology of Ospedale Maggiore di Milano. Cultivation of Candida albicans was carried out on a Sabouraud agar inclined plate, and periodically transferred to a Sabouraud agar plate, and cultured at 28°C for 48 hours. In order to prepare the quiescent yeast, the colonies were picked from the agar plate, transferred to 30 ml Sabouraud glucose liquid medium, and cultured at 32°C for 72 hours. The obtained cells were centrifuged at 1000xg for 10 minutes, and the deposited cells were washed twice with distilled water. Then count the number of cells and suspend them in Hank's Balanced Salt Solution (HBSS) to the required concentration. Through the 0.01% methyl blue efflux test to determine the viability of bacteria. The results showed th...

Embodiment III

[0050] The purpose of this example is to compare the antibacterial activity of α-MSH and / or its derivatives with fluconazole, which is an approved antifungal drug.

[0051] Detection of α-MSH (1-13) (serial number 4), (4-10) (serial number 2), (6-13) (serial number 3), (11-13) (serial number 1 ) And ACTH (1-39), (18-39) and fluconazole in 10 -6 -10 -4 The ability to resist Candida albicans at M concentration is the same as in Example II. Figure 4 shows that compared with fluconazole, α-MSH (11-13) (serial number 1), (4-10) (serial number 2), (6-13) (serial number 3) and (1-13) (Sequence No. 4) is very effective against Candida albicans, and its inhibitory activity is similar to that of fluconazole at equimolar concentrations. In contrast, the core α-MSH sequence (4-10) (sequence number 2) with behavioral effects but very little anti-inflammatory activity produced nearly 50% of the colony forming unit inhibitory effect. Although this inhibitory effect is significant (p-4 At M conce...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a dimmer formed by one or more polypeptides for treating uro-genital conditions. Uro-genital conditions can include infections, inflammation, or both. In one preferred embodiment of the invention, the uro-genital condition includes infection and / or inflammation of the vagina, vulva, urinary tract, penis, and / or the rectum. In another preferred embodiment of the invention, the one or more polypeptides are dissolved in a carrier. In another preferred embodiment of the invention, the one or more polypeptides are associated with a tampon for preventing toxic shock syndrome. In another preferred embodiment, the one or more polypeptides are associated with a contraceptive for prevention of sexually transmitted diseases or infections. In another preferred embodiment, the one or more polypeptides are associated with a suppository for insertion into the vagina or rectum.

Description

[0001] Divisional Statement [0002] This application is a divisional application of the Chinese patent application filed on March 23, 2000 with the application number 200410038019. 1, and the invention title is "a therapeutic system for genitourinary diseases"; and 200410038019.1 was filed on March 23, 2000 The divisional application of the Chinese patent application with the application number of 00807953.6 (PCT / US00 / 07846) and the title of the invention is "a treatment system for genitourinary diseases". This application claims priority to US Provisional Patent Application 60 / 126,233, which is entitled "Antimicrobial Amino Acid Sequence Derived from α-Melanocyte Stimulating Hormone", filed on March 24, 1999. Technical field [0003] The invention is used for the treatment of genitourinary system diseases, and particularly relates to the treatment of urogenital system diseases by polypeptides and dimers. Background technique [0004] Urogenital diseases usually affect both sexes...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/08A61K38/16A61K9/06A61K9/12A61K9/20A61P31/02A61P31/04A61P31/10A61P31/12A61P15/02A61K9/02A61F13/20A61K9/00A61K9/107A61K38/00A61K38/07A61K38/34A61P13/00A61P15/00A61P15/18A61P29/00A61P31/18C07K5/09C07K5/103C07K7/06C07K7/08C07K14/575
CPCA61K38/34A61K38/07A61K9/0034A61P13/00A61P15/00A61P15/18A61P29/00A61P31/02A61P31/04A61P31/10A61P31/12A61P31/18
Inventor 詹姆斯·利普顿安娜·卡塔尼亚
Owner ZENGEN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com